2 active not recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) Next Generation Dome Helmet Focused Ultrasound, Intravenous immunoglobulin (IVIG), 10% solution for infusion, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension - Amyotrophic Lateral Sclerosis, ALS | Phase 1 | Active not recruiting | Sunnybrook Health Sciences Centre | 6 | 2025-04-15 | 2026-07-14 |
| Adenosine 2A Receptor Antagonism and AIH in ALS Consume 20mg of istradefylline, Low Oxygen therapy, Placebo counterpart to the istradefylline drug - ALS | Phase 1 / Phase 2 | Active not recruiting | University of Florida | 40 | 2022-06-21 | 2026-03-27 |
Amyotrophic Lateral Sclerosis (1) · Hypoxia (1) · Motor Neuron Disease (1) · Respiratory Aspiration (1)
Central Nervous System Diseases (1) · Metabolic Diseases (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Nutritional and Metabolic Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Proteostasis Deficiencies (1) · Respiration Disorders (1) · Respiratory Tract Diseases (1) · Signs and Symptoms (1) · Signs and Symptoms, Respiratory (1) · Spinal Cord Diseases (1) · TDP-43 Proteinopathies (1)
Immunoglobulins, Intravenous (1) · Insemination, Artificial, Homologous (1) · Solutions (1) · istradefylline (1)
Sunnybrook Health Sciences Centre (1) · University of Florida (1)
Canada (1) · United States (1)
Barbara Smith (1)